InMed Pharmaceuticals Inc. (INM)

A. Company Overview

InMed Pharmaceuticals Inc. is a clinical stage pharmaceutical company focused on developing prescription-based products to treat diseases with high unmet medical needs. The company's pipeline includes rare cannabinoids and novel cannabinoid analogs, with the goal of providing new therapeutic alternatives to patients and consumers who may benefit from cannabinoid-based products.

B. Products and Services

In collaboration with its subsidiary BayMedica, LLC, InMed Pharmaceuticals is also engaged in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. The company is conducting research and development on multiple manufacturing approaches, including chemical synthesis, biosynthesis, and its proprietary integrated manufacturing approach called IntegraSynTM. These approaches aim to synthesize rare cannabinoids for use in pharmaceutical product candidates and products.

The company's current pharmaceutical drug product candidates are topically applied and include INM-755 for Epidermolysis bullosa (EB) and INM-088 for glaucoma. These drug candidates utilize cannabinol (CBN) as the active pharmaceutical ingredient (API). In addition to their current uses, potential additional applications of INM-755 and INM-088, as well as novel cannabinoid analogs, are being explored for treating neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's.

C. Strategy

InMed Pharmaceuticals aims to develop multiple pharmaceutical product candidates based on rare cannabinoid compounds. The company seeks to differentiate itself from currently approved cannabinoid therapies, which primarily rely on CBD and THC and are often administered orally. In contrast, InMed Pharmaceuticals intends to deliver its rare cannabinoid drug candidates through topical formulations, such as creams for dermatology and eye drops for ocular diseases. This approach allows for targeted treatment at the site of the disease while minimizing systemic exposure and associated unwanted side effects.

D. Marketing and Target Group

InMed Pharmaceuticals' marketing efforts focus on reaching healthcare professionals, patients, and consumers who may benefit from cannabinoid-based products. The company aims to highlight the potential therapeutic benefits attributed to the Cannabis plant, while emphasizing the scientific approaches utilized to develop non-plant-derived (synthetically manufactured) cannabinoid compounds. The target group includes individuals with diseases and conditions that may be alleviated by cannabinoid-based treatments, as well as wholesalers and end-product manufacturers that utilize the company's cannabinoid ingredients in various product formats.

E. Employees and Human Capital

InMed Pharmaceuticals is led by a highly experienced management team comprised of pharmaceutical and biotechnology executives. Each team member possesses over 20 to 30 years of industry experience in various areas, including drug discovery, preclinical research, formulation development, manufacturing, clinical trials, regulatory affairs, and commercialization. The management team is supplemented by a board of directors with extensive experience in the pharmaceutical and biotechnology industries.

As of September 1, 2022, InMed Pharmaceuticals employed 13 full-time employees and also engaged several consultants. The company maintains good relations with its employees, as none of them are represented by a collective bargaining agreement, and there have been no work stoppages.